


Reinstatement Spotlight

January 13, 2023

Reinstatement Phase II – Phase IV



The *Reinstatement Spotlight* is a weekly publication released every Friday throughout reinstatement to provide essential information and resources for health plans, pharmacies, and prescribers.

What Happened This Week

- Release of the [How To Prepare for Retirement of the Transition Policy](#) alert

What's Happening Next Week

- Reinstatement of Prior Authorization Requirements for 39 Drug Classes begins January 20, 2023.

Upcoming

- Beginning Friday, February 3, 2023: Phase II Reinstatement Webinar – Attend an in-person webinar regarding Phase II Reinstatement by joining via [Zoom](#) at 12 p.m. on Fridays. No registration is required. This webinar will provide information specific to Phase II, Wave 2 including reinstatement of prior authorization (PA) requirements for beneficiaries 22 years

of age and older, as well as discussion about the submission of PAs in advance of the retirement of the Transition Policy.

Reinstatement Resources

- [Medi-Cal Rx Reinstatement of Prior Authorizations and Retirement of the Transition Policy \(Phases II, III, and IV\)](#) – This slide deck presents the approach, timeline, and available resources for Reinstatement Phases II, III, and IV.
- [90-Day Countdown – Phase III: Retirement of the Transition Policy for Beneficiaries 22 Years of Age and Older](#)
- [30-Day Countdown – Reinstatement of Prior Authorization Requirements for 39 Drug Classes](#)
- [Medi-Cal Rx Phase II – Frequently Asked Questions \(FAQs\)](#)
- [Medi-Cal Rx Approved NDC List](#) with Phase II, Wave 1 reinstated Standard Therapeutic Classes (STCs).

For more information, visit [Medi-Cal Rx Education & Outreach](#) and select **Medi-Cal Rx Reinstatement** from the menu.

Stay up to date with all that is happening at Medi-Cal Rx by visiting the [Bulletins & News](#) page and signing up for the [Medi-Cal Rx Subscription Service](#) to receive notification of future alerts.



Plan ahead! Review the Medi-Cal Rx [Covered Products Lists](#). There may be clinically appropriate therapy alternatives that do not require a PA.